Literature DB >> 17336394

Distinct tissue cytokine and chemokine mRNA expression in canine sino-nasal aspergillosis and idiopathic lymphoplasmacytic rhinitis.

D Peeters1, I R Peters, C R Helps, A Gabriel, M J Day, C Clercx.   

Abstract

Idiopathic lymphoplasmacytic rhinitis (LPR) and sino-nasal aspergillosis (SNA) are among the most common causes of nasal discharge in dogs. The pathogenesis of both diseases is poorly understood. Some have proposed that LPR is a chronic inflammatory response to an inhaled irritant, pollutant or allergen, but others suggest that most cases of LPR constitute undiagnosed cases of SNA. Local immune dysfunction is thought to permit opportunist infection in canine SNA. This study investigates the nature of the local tissue immune response mounted in canine LPR and SNA in order to determine whether these diseases have similar or distinct pathogenesis. Quantitative reverse transcriptase polymerase chain reaction was carried out on RNA isolated from nasal biopsies from diseased and control dogs, using specific assays designed to amplify messenger RNA (mRNA), encoding a panel of cytokines and chemokines. SNA was associated with significantly increased expression of mRNA encoding interleukin (IL)-6, IL-8, IL-10, IL-12p19, IL-12p35, IL-12p40, IL-18, IFN-gamma, TNF-alpha, TGF-beta, eotaxin-2 and all four monocyte chemoattractant proteins (MCPs) relative to controls. LPR was associated with significantly increased expression of mRNA encoding IL-5, IL-8, IL-10, IL-12p19, IL-12p40, IL-18, TNF-alpha, TGF-beta, MCP-2 and MCP-3 relative to controls. There was significantly more expression of mRNA encoding IL-6, IL-8, IL-10, IL-12p35, IL-12p40, IL-18, IFN-gamma, TNF-alpha, TGF-beta and all MCPs, and significantly less expression of IL-5 in dogs with SNA than in dogs with LPR. Thus, the profile of cytokine and chemokine gene expression in the nasal mucosa is different in dogs with LPR when compared to dogs with SNA. A partial Th2 immune response appears to be mounted in the nasal mucosa of dogs with LPR, whereas the mucosal immune response in canine SNA is of the Th1 type. Increase in IL-10 and TGF-beta transcripts in dogs with SNA is thought to be implicated in the failure to clear the Aspergillus infection. These results constitute the first evidence that the pathogenesis of canine LPR and SNA is distinct.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336394     DOI: 10.1016/j.vetimm.2007.01.018

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

Review 1.  The immunopathology of canine vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

2.  Evaluation of Serum Aspergillus-Specific Immunoglobulin A by Indirect ELISA for Diagnosis of Feline Upper Respiratory Tract Aspergillosis.

Authors:  A Taylor; I Peters; N K Dhand; J Whitney; L R Johnson; J A Beatty; V R Barrs
Journal:  J Vet Intern Med       Date:  2016-09-01       Impact factor: 3.333

3.  The sino-nasal warzone: transcriptomic and genomic studies on sino-nasal aspergillosis in dogs.

Authors:  I D Valdes; A B P Hart de Ruijter; C J Torres; J C A Breuker; H A B Wösten; H de Cock
Journal:  NPJ Biofilms Microbiomes       Date:  2020-11-12       Impact factor: 7.290

4.  Oxytocin-stimulated NFAT transcriptional activation in human myometrial cells.

Authors:  Jason N A Pont; Craig A McArdle; Andrés López Bernal
Journal:  Mol Endocrinol       Date:  2012-08-17

5.  The evaluation of three treatment protocols using oral prednisone and oral meloxicam for therapy of canine idiopathic lymphoplasmacytic rhinitis: a pilot study.

Authors:  Ewa Kaczmar; Andrzej Rychlik; Marta Szweda
Journal:  Ir Vet J       Date:  2018-10-03       Impact factor: 2.146

6.  Bilateral orbital and nasal aspergillosis in a cat.

Authors:  Laura Barachetti; Carlo M Mortellaro; Mauro Di Giancamillo; Chiara Giudice; Pieranna Martino; Olga Travetti; Paul E Miller
Journal:  Vet Ophthalmol       Date:  2009 May-Jun       Impact factor: 1.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.